328 related articles for article (PubMed ID: 30770285)
1. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
Harrison RP; Zylberberg E; Ellison S; Levine BL
Cytotherapy; 2019 Feb; 21(2):224-233. PubMed ID: 30770285
[TBL] [Abstract][Full Text] [Related]
2. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
3. Manufacturing chimeric antigen receptor T cells: issues and challenges.
Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
[TBL] [Abstract][Full Text] [Related]
4. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
5. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
Moradi V; Omidkhoda A; Ahmadbeigi N
Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
[TBL] [Abstract][Full Text] [Related]
6. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy.
Tempero M
J Natl Compr Canc Netw; 2017 Oct; 15(10):1179. PubMed ID: 28982741
[No Abstract] [Full Text] [Related]
7. Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.
Hamieh M; Sadelain M
Trends Mol Med; 2018 Sep; 24(9):729-731. PubMed ID: 30149852
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon.
Martino M; Naso V; Loteta B; Canale FA; Pugliese M; Alati C; Musuraca G; Nappi D; Gaimari A; Nicolini F; Mazza M; Bravaccini S; Derudas D; Martinelli G; Cerchione C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362130
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation.
Lee NK; Chang JW
Ann Lab Med; 2024 Jul; 44(4):314-323. PubMed ID: 38361427
[TBL] [Abstract][Full Text] [Related]
10. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
11. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
Torikai H; Cooper LJ
Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
[TBL] [Abstract][Full Text] [Related]
12. Advances and Challenges of CAR T Cells in Clinical Trials.
Holzinger A; Abken H
Recent Results Cancer Res; 2020; 214():93-128. PubMed ID: 31473850
[TBL] [Abstract][Full Text] [Related]
13. Manufacturing innovation to drive down cell therapy costs.
Khang M; Suryaprakash S; Kotrappa M; Mulyasasmita W; Topp S; Wu J
Trends Biotechnol; 2023 Oct; 41(10):1216-1219. PubMed ID: 37236813
[TBL] [Abstract][Full Text] [Related]
14. Cell and gene therapies at the forefront of innovative medical care: Implications for South Africa.
Pepper MS; Alessandrini M; Pope A; Van Staden W; Green RJ
S Afr Med J; 2018 Dec; 109(1):20-22. PubMed ID: 30606299
[TBL] [Abstract][Full Text] [Related]
15. A guide to manufacturing CAR T cell therapies.
Vormittag P; Gunn R; Ghorashian S; Veraitch FS
Curr Opin Biotechnol; 2018 Oct; 53():164-181. PubMed ID: 29462761
[TBL] [Abstract][Full Text] [Related]
16. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
Fang Z; Han H; Liang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race.
Harrer DC; Dörrie J; Schaft N
Hum Gene Ther; 2018 May; 29(5):547-558. PubMed ID: 29320890
[TBL] [Abstract][Full Text] [Related]
18. Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities.
Kansagra A; Farnia S; Majhail N
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-8. PubMed ID: 32347759
[TBL] [Abstract][Full Text] [Related]
19. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
[TBL] [Abstract][Full Text] [Related]
20. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]